CIK 1587114
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 87.59% | 25 |
| Unclassified | 12.41% | 4 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc. | Health Care | 24.58% |
| 2 | ANAB | ANAPTYSBIO, INC | Health Care | 18.68% |
| 3 | JAZZ | Jazz Pharmaceuticals plc | Health Care | 13.79% |
| 4 | CENTESSA PHARMACEUTICALS PLC | Unclassified | 10.18% | |
| 5 | CRNX | Crinetics Pharmaceuticals, Inc. | Health Care | 6.66% |
| 6 | AKTS | Aktis Oncology, Inc. | Health Care | 3.69% |
| 7 | ORIC | Oric Pharmaceuticals, Inc. | Health Care | 3.64% |
| 8 | CGON | CG Oncology, Inc. | Health Care | 3.19% |
| 9 | CRSP | CRISPR Therapeutics AG | Health Care | 2.82% |
| 10 | ETON | Eton Pharmaceuticals, Inc. | Health Care | 2.29% |
25/29 names classified · sector 87.6% of weight · industry 87.6% · mkt cap 83.9%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 87.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (1/29 names) · unclassified 100.0%: ZYME, ANAB, JAZZ, , CRNX, AKTS, ORIC, CGON, CRSP, ETON +18 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | ZYMEZYMEWORKS INC | 22,970,388 | $575M | 24.6% | HOLD |
| 2 | ANABANAPTYSBIO INC | 7,880,094 | $437M | 18.7% | HOLD |
| 3 | JAZZJAZZ PHARMACEUTICALS PLC | 1,706,469 | $323M | 13.8% | HOLD |
| 4 | CENTESSA PHARMACEUTICALS PLC | 6,000,000 | $238M | 10.2% | ADD 93% |
| 5 | CRNXCRINETICS PHARMACEUTICALS IN | 4,288,120 | $156M | 6.7% | HOLD |
| 6 | AKTSAKTIS ONCOLOGY INC | 4,824,469 | $86M | 3.7% | NEW |
| 7 | ORICORIC PHARMACEUTICALS INC | 6,728,116 | $85M | 3.6% | HOLD |
| 8 | CGONCG ONCOLOGY INC | 1,102,000 | $75M | 3.2% | ADD 43% |
| 9 | CRSPCRISPR THERAPEUTICS AG | 1,389,276 | $66M | 2.8% | HOLD |
| 10 | ETONETON PHARMACEUTICALS INC | 2,171,938 | $54M | 2.3% | ADD 7% |
| 11 | LKFTGALAPAGOS NV | 1,667,119 | $50M | 2.1% | HOLD |
| 12 | XNCRXENCOR INC | 2,183,000 | $26M | 1.1% | TRIM −33% |
| 13 | NGNENEUROGENE INC | 1,271,342 | $26M | 1.1% | HOLD |
| 14 | BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | 2,823,126 | $25M | 1.1% | HOLD |
| 15 | MBXMBX BIOSCIENCES INC | 777,000 | $23M | 1.0% | TRIM −63% |
| 16 | RLAYRELAY THERAPEUTICS INC | 1,904,762 | $19M | 0.8% | NEW |
| 17 | ZBIOZENAS BIOPHARMA INC | 789,500 | $15M | 0.7% | HOLD |
| 18 | ERASERASCA INC | 900,000 | $15M | 0.6% | NEW |
| 19 | EIKNEIKON THERAPEUTICS INC | 732,606 | $8M | 0.3% | NEW |
| 20 | REPLREPLIMUNE GROUP INC | 1,000,000 | $8M | 0.3% | NEW |
| 21 | ZURAZURA BIO LTD | 1,179,715 | $7M | 0.3% | NEW |
| 22 | PHATPHATHOM PHARMACEUTICALS INC | 625,000 | $7M | 0.3% | NEW |
| 23 | MREOMEREO BIOPHARMA GROUP PLC | 13,368,855 | $4M | 0.2% | ADD 70% |
| 24 | STOKSTOKE THERAPEUTICS INC | 100,000 | $3M | 0.1% | NEW |
| 25 | PRLDPRELUDE THERAPEUTICS INC | 947,049 | $3M | 0.1% | NEW |
| 26 | IBIOIBIO INC | 1,583,000 | $3M | 0.1% | TRIM −29% |
| 27 | HLXCHELIX ACQUISITION CORP III | 200,000 | $2M | 0.1% | NEW |
| 28 | ATRAATARA BIOTHERAPEUTICS INC | 99,593 | $471,075 | 0.0% | TRIM −83% |
| 29 | SRZNWSURROZEN INC | 4,444 | $129,454 | 0.0% | HOLD |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| ZYMEZYMEWORKS INC | 15.0M | 17.3M | 23.0M | 23.0M | 23.0M | 23.0M | $575M |
| ANABANAPTYSBIO INC | 7.9M | 7.9M | 7.9M | 7.9M | 7.9M | 7.9M | $437M |
| JAZZJAZZ PHARMACEUTICALS PLC | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | 1.7M | $323M |
| CENTESSA PHARMACEUTICALS PLC | — | — | — | 550K | 3.1M | 6.0M | $238M |
| CRNXCRINETICS PHARMACEUTICALS IN | 4.3M | 4.3M | 4.3M | 4.3M | 4.3M | 4.3M | $156M |
| AKTSAKTIS ONCOLOGY INC | — | — | — | — | — | 4.8M | $86M |
| ORICORIC PHARMACEUTICALS INC | 3.4M | 3.4M | 1.6M | 6.7M | 6.7M | 6.7M | $85M |
| CGONCG ONCOLOGY INC | — | — | — | — | 772K | 1.1M | $75M |
| CRSPCRISPR THERAPEUTICS AG | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | 1.4M | $66M |
| ETONETON PHARMACEUTICALS INC | 1.8M | 1.9M | 2.0M | 2.0M | 2.0M | 2.2M | $54M |
| LKFTGALAPAGOS NV | 155K | 155K | 1.0M | 1.7M | 1.7M | 1.7M | $50M |
| XNCRXENCOR INC | 6.1M | 6.1M | 6.1M | 6.1M | 3.3M | 2.2M | $26M |
| NGNENEUROGENE INC | 1.3M | 1.3M | 1.3M | 1.3M | 1.3M | 1.3M | $26M |
| BBOTBRIDGEBIO ONCOLOGY THERAPEUTIC | — | — | — | 2.8M | 2.8M | 2.8M | $25M |
| MBXMBX BIOSCIENCES INC | 1.3M | 1.3M | 1.1M | 2.1M | 2.1M | 777K | $23M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
